EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Prognostic role of early prostate specific antigen changes after [ 177 Lu ] Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis

Luca Giovanella iD, Maria Luisa Garo iD, Marco Cuzzocrea, Gaetano Paone, Ken Herrmann

European Journal of Clinical Investigation · 2023

DOI: 10.1111/eci.14014 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Clinical Investigation, 2023. Verfasst von Luca Giovanella und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approximately 10%–20% of prostate cancers progress to metastatic and castration‐resistant forms (mCRPC). Radioligand (RLT) therapy with [ 177 Lu]Lu‐prostate‐specific membrane antigen (PSMA) is an emerging treatment for metastasized mCRPC and its efficacy is assessed not only but also by prostate specific antigen (PSA) measurement after 12 weeks or more after treatment. Our aim was to evaluate the role of early PSA measurement after RLT in predicting overall survival (OS) of mCRPC patients.

Methods

A systematic search on PubMed, Web Of Science and Scopus was performed from January to December 2022. PRISMA guidelines for prognostic studies was adopted. Risk of bias was assessed using quality of prognostic studies (QUIPS).

Results

Twelve studies at low‐intermediate risk of bias, were included in the meta‐analysis (1646 patients, mean age 70 years). About 50% of patients showed a PSA decline after 1–2 of [ 177 Lu]Lu‐PSMA, and more than 30% reported a PSA decline ≥50%. The median OS range for patients with any PSA decline was 13–20 months, while for patients with stable or increased PSA, the median OS fell to 6–12 months. The OS rate for a PSA decline after the one‐two [ 177 Lu]Lu‐PSMA cycles was 0.39 (95% CI: 0.31–0.50), while OS for a PSA decline ≥50% was 0.69 (95% CI: 0.57–0.83).

Conclusions

A PSA decline is observed in almost 50% of mCRPC patients after 1–2 [ 177 Lu]Lu‐PSMA cycles, with a significantly longer OS compared to stable or increased PSA levels, respectively. Accordingly, any PSA decline after 1–2 cycles of therapy should be regarded as a favourable prognostic factor for OS .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansAgedPrognosisTreatment OutcomeProstateDipeptidesRetrospective Studies

Stichwörter der Autor:innen

[177Lu]Lu-prostate specific membrane antigenearly responsemetastatic castration resistantoverall survivalprostate cancerprostate specific antigen

Substanzen

Prostate-Specific AntigenDipeptides

Autor:innen und Institutionen

  • Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Clinic for Nuclear Medicine, University Hospital of Zürich, Zürich, Switzerland.
  • Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Research Unit of Cardiac Surgery, Department of Cardiovascular Surgery, Università Campus Bio-Medico, Rome, Italy.
  • Clinic for Nuclear Medicine, Essen University Hospital, Essen, Germany.

ORCID-Profile: Luca Giovanella, Maria Luisa Garo

Zitieren

APA

Giovanella, L., Garo, M. L., Cuzzocrea, M., Paone, G., & Herrmann, K. (2023). Prognostic role of early prostate specific antigen changes after [ 177 Lu ] Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14014

Vancouver

Giovanella L, Garo ML, Cuzzocrea M, Paone G, Herrmann K. Prognostic role of early prostate specific antigen changes after [ 177 Lu ] Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis. European Journal of Clinical Investigation. 2023. doi:10.1111/eci.14014

BibTeX
@article{Giovanella2023,
  author = {Giovanella, Luca and Garo, Maria Luisa and Cuzzocrea, Marco and Paone, Gaetano and Herrmann, Ken},
  title = {Prognostic role of early prostate specific antigen changes after [ 177 Lu ] Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis},
  journal = {European Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1111/eci.14014}
}
Kostenlos starten →